Grants for For profit organizations other than small businesses - Science and Technology

The Academy of Kidney Cancer Investigators (AKCI) is a unique, interactive virtual academy that provides, intensive mentoring, national networking, and a peer group for scientist and clinician junior faculty. The KCRP created the Academy of Kidney Cancer Investigators in FY19 to align with several program priorities, which include to build research capacity in kidney cancer; increase collaborations to advance kidney cancer research, and support innovative research conducted by the next generation of kidney cancer scientists and clinicians. The overarching goal of the AKCI is to increase research capacity in kidney cancer through the development of successful, highly productive kidney cancer researchers in a collaborative research and training environment. The AKCI is a virtual career development and research training platform that currently consists of 11 Early-Career Scholars (ECS)/Designated Mentor pairs from different institutions, and one Academy Director. It is expected that six Early-Career Scholars will graduate by the fall of 2025 and four FY23 AKCI Early-Career Scholars/Designated Mentor awards will be made by September 2024. In addition, Academy graduates will continue to participate in the annual Academy meetings. Information about the Academy is available on the KCRP webpage and in the Kidney Cancer Program Booklet at https://cdmrp.health.mil/kcrp. The AKCI leadership team will identify opportunities for engagement with KCRP AKCI Scholars-Designated Mentors and KCRP FY25 (and subsequent year awardees) Postdoctoral and Clinical Fellowship Awardees. The Academy Director and Deputy Director catalyze the growth and professional development of the Early-Career Scholars in collaboration with their Designated Mentors, assess the progress of the ECSs, and facilitate communication and collaboration among all of the Academy members. The AKCI leadership team will also identify and offer opportunities for engagement (e.g., invitations to seminar series and in-person meetings) with FY24 Postdoctoral and Clinical Fellowship Awardees with FY24 KCRP AKCI-ECS-Designated Mentors (and subsequent year awardees). This FY24 funding opportunity is soliciting applications for an Academy Director (Principal Investigator [PI]) and Deputy Director (Partnering PI) to lead the AKCI. The newly selected FY24 Academy Director and Deputy Director will initiate their responsibilities no later than October 2025. The Academy Director and Deputy Director (hereafter referred to as Academy Leadership) must be established kidney cancer researchers and can be at different institutions. The Academy Leadership must demonstrate a strong record of mentoring and training early career investigators, a commitment to leadership, the ability to articulate methods toward research collaborations, and the ability to objectively assess the progress of all Scholars with their Designated Mentors in the AKCI. Other objectives will include execution of research that will engage AKCI FY24 Scholars (including subsequent-year Scholars), develop tools for Scholars to enable success, and provide opportunities to broaden their knowledge in kidney and renal pelvis cancers. The leadership team will identify and offer occasion(s) for the AKCI to network with KCRP FY24 Postdoctoral and Clinical Fellowship Awardees (and subsequent year awardees). Designated Mentors on FY24 KCRP AKCI Early-Career Scholar Award applications and Designated Mentors on open FY19 through FY23 KCRP AKCI Early-Career Scholar Awards (with the exception of those graduating in 2024) are not eligible to apply for this award. Note: An invited oral presentation is a requirement for application review of the KCRP AKCI LA, as described in Section II.D.2.b.iv, Additional Application Components. Responsibilities of the Academy Leadership include, but are not limited to: Act as a resource for all Scholars and Designated Mentors in the Academy over the Scholars 4-year period of performance. Facilitate communication and collaboration among all Scholars and Designated Mentors (including periodic interactive communication among all Academy members). Develop assessment criteria to evaluate the research progress made by all Scholars, as well as their career progression and sustainment as independent investigators in kidney cancer research. Conduct collaborative kidney cancer pilot project(s) that include Academy Scholars. These pilot projects should have the potential to improve collaboration within the Academy, as well as impact kidney cancer research and/or kidney cancer patients/survivors. o Examples of pilot research projects may include but are not limited to (a) funding an extended statistical or bioinformatics analysis with AKCI Scholars, (b) performing a large-scale meta-analysis of human or animal datasets with AKCI scholars, (c) provide access to critical biorepositories or animal models to expand AKCI investigator analyses or increase study rigor. Provide constructive critiques with the goal of advancing the research and professional careers of the Scholars and strengthening the mentorship of the Designated Mentors. Provide avenues to increase the promotion of the Academy and visibility of Scholars within kidney cancer research and advocacy communities (e.g., peer review, conferences, editorial boards). Support the professional development, to include laboratory management skills, of the Scholars into leading researchers through invited presentations by experts outside of the AKCI LA. Plan and host an annual 1-day workshop and, biennially, a multi-day workshop for all Scholars/Designated Mentor pairs as well as Academy graduates to present their research, share knowledge, and develop collaborative efforts within the AKCI. Scholars will be responsible for their own travel costs to in-person Academy meetings. Include KCRP FY24 Postdoctoral and Clinical Fellowship Awardees in at least one meeting of the FY24 AKCI. These investigators will be responsible for their own travel costs, funds for which are included in their research awards. Establish a panel of patient advocates and Veteran(s) (i.e., the Patient Advocacy Panel) to inform the AKCI on the needs of the patient community. Establish the Designated Mentor Panel to facilitate collaborations among the AKCI participants including the Scholars, Academy Director/Deputy Director, and the Designated Mentors. The Academy of Kidney Cancer Investigators Leadership Award is structured to support two PIs. The Academy Director will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. The Deputy Director will be identified as the Partnering PI. The collaboration between the Academy Director and the Deputy Director should be supported by complementary expertise and experience. Initiating and Partnering PIs each have different submission requirements, as described in Section II.D.2, Content and Form of the Application Submission; however, both PIs should contribute significantly to the development of the proposed research project. The application should clearly demonstrate that both PIs have equal levels of input on the proposed Academy Leadership and clearly define the components to be addressed by each to support the success of the Scholars. While it is up to the Academy Director and the Deputy Director to define their roles, both Academy Leaders should have interactions with each Scholar-Designated Mentor pair, (and the Scholars Designated Mentors); acting as administrative support does not fulfill the intent of the Director and Deputy Director. If recommended for funding, each PI will be named on separate awards to the recipient organization(s). Each award will be subject to separate reporting, regulatory, and administrative requirements. For individual submission requirements for the Initiating and Partnering PI(s), refer to Section II.D.2, Content and Form of the Application Submission. Organizational-Level Emphasis: The following areas of emphasis are broadly applicable to many CDMRP programs, not just the KCRP. Investigators are encouraged to consider addressing these areas in their applications if doing so is appropriate for their line of research, addresses the FY24 KCRP strategic priorities and/focus areas described in Section II.A.1 and Section II.A.2. Nuclear Medicine: Innovative research involving nuclear medicine and related techniques to support early diagnosis, more effective treatment, and improved health outcomes of active-duty Service Members and their Families is encouraged. Such research could improve diagnostic and targeted treatment capabilities through noninvasive techniques and may drive the development of precision imaging and advanced targeted therapies. Womens Health: CDMRP encourages research on health areas and conditions that affect women uniquely, disproportionately, or differently from men, including studies analyzing sex as a biological variable. Such research should relate anticipated project findings to improvements in womens health outcomes and/or advancing knowledge for womens health. Metastatic Cancer Task Force: A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-Cancer-Research) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY24 KCRP priorities. Rigorous Study Design: All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research. The standards are described in SC Landis et al., 2012, A call for transparent reporting to optimize the predictive value of preclinical research, Nature 490:187-191 (https://www.nature.com/nature/journal/v490/n7419/full/nature11556.html). While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies. Military Service Involvement: Applications from investigators within the military services and applications involving multidisciplinary collaborations among academia, industry, the military services, the U.S. Department of Veterans Affairs (VA), and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, and/or their Families. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research. Clinical trials are not allowed under this funding opportunity. A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes. Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials. For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes: (1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies. (2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. (3) Outcomes research and health services research that do not fit under the definition of clinical trial. Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule. The funding instrument for awards made under the program announcement will be cooperative agreements (31 USC 6305). Substantial CDMRP programmatic involvement with recipients is anticipated during the performance of award activities. Substantial involvement means that, after award, CDMRP staff will assist, guide, coordinate, or participate in project activities including but not limited to: Participating in the Steering Committee that oversees study conduct. Make recommendations for continued funding based on (a) overall study progress, including sufficient patient and/or data accrual; (b) cooperation in carrying out the research (e.g., attendance at Steering Committee meetings, implementation of group decisions, compliance with the terms of award and reporting requirements); and/or (c) maintenance of a high quality of research. The anticipated combined direct costs budgeted for the entire period of performance for a FY24 KCRP AKCI LA should not exceed $1,500,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information. Awards supported with FY24 funds will be made no later than September 30, 2025. The CDMRP expects to allot approximately $2.4M to fund approximately one KCRP Academy of Kidney Cancer Investigator Leadership Award application (consisting of an Initiating PI application and a Partnering PI application). Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 and FY26 funds, which will expire for use on September 30, 2030, and September 30, 2032, respectively.

The CDMRP Neurofibromatosis Clinical Trial Award is designed to support the implementation of clinical trials that aim to significantly improve the treatment or management of Neurofibromatosis, encouraging collaborations among various sectors including academia, industry, military services, and federal agencies.

The FY24 KCRP Concept Award supports highly innovative, untested, potentially groundbreaking novel concepts in kidney cancer. The Concept Award is not intended to support an incremental progression of an already established research project but, instead, it allows Principal Investigators (PIs) the opportunity to pursue serendipitous observations. Preliminary data are not allowed and should not be discussed. This award mechanism supports high-risk studies that have the potential to reveal entirely new avenues for investigation. Applications must describe how the new idea will enhance the existing knowledge of kidney cancer or develop an innovative and novel course of investigation. Research completed through a Concept Award may generate sufficient preliminary data to enable the PI to prepare an application for future research.Organizational-Level Emphasis Areas:The following areas of emphasis are broadly applicable to many CDMRP programs, not just the KCRP. Investigators are encouraged to consider addressing these areas in their applications if doing so is appropriate for their line of research, addresses the FY24 KCRP strategic priorities and/or focus areas described in Section II.A.1 and Section II.A.2.Nuclear Medicine: Innovative research involving nuclear medicine and related techniques to support early diagnosis, more effective treatment, and improved health outcomes of active-duty Service Members and their Families is encouraged. Such research could improve diagnostic and targeted treatment capabilities through noninvasive techniques and may drive the development of precision imaging and advanced targeted therapies.Womens Health: CDMRP encourages research on health areas and conditions that affect women uniquely, disproportionately, or differently from men, including studies analyzing sex as a biological variable. Such research should relate anticipated project findings to improvements in womens health outcomes and/or advancing knowledge for womens health.Metastatic Cancer Task Force: A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-Cancer-Research) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY24 KCRP priorities.Rigorous Study Design: All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research. The standards are described in SC Landis et al., 2012, A call for transparent reporting to optimize the predictive value of preclinical research, Nature 490:187-191 (https://www.nature.com/nature/journal/v490/n7419/full/nature11556.html). While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies.Military Service Involvement: Applications from investigators within the military services and applications involving multidisciplinary collaborations among academia, industry, the military services, the U.S. Department of Veterans Affairs (VA), and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, and/or their Families. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research.Reviewers will be blinded to the identity of the Principal Investigator (PI), collaborator(s), and their organization(s). Refer to Section II.D.2.b.i, Full Application Guidelines, for more information.Clinical trials are not allowed under this funding opportunity.A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes:(1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies.(2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.(3) Outcomes research and health services research that do not fit under the definition of clinical trial.Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule.The funding instrument for awards made under the program announcement will be grants (31 USC 6304).The anticipated direct costs budgeted for the entire period of performance for an FY24 KCRP Concept Award should not exceed $100,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.Awards supported with FY24 funds will be made no later than September 30, 2025.The CDMRP expects to allot approximately $1.44M to fund approximately nine Concept Award applications. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.

This funding opportunity supports educational projects that enhance training for technicians in high-technology fields, particularly at two-year colleges, while fostering partnerships with industry and addressing workforce needs.

The PMGP was started in 1970 to support research in the field of fundamental measurement or the determination of fundamental constants, enabling the faculties at universities and colleges and laboratory researchers to conduct significant research in this area. By funding the research projects of eligible applicants through this program, NIST supports advances in fundamental measurement, the determination of fundamental constants, and fosters extramural collaboration with NIST scientists.

The Women’s Philanthropy Society is accepting applications to leave a legacy of love an enduring gift for generations to come across a broad spectrum of issues impacting community’s quality of life. Donor Name: Women’s Philanthropy Society State: Alabama County: Limestone County (AL), Madison County (AL) Type of Grant: Grant Deadline: (mm/dd/yyyy) 07/10/2024 Size of the Grant: $10,000 to $100,000 Grant Duration: Grant Duration Not Mentioned Details: Focus Areas For 2024, the Women’s Philanthropy Society has chosen the focus issue of Health & Wellness.  Funding information  $50,000 (Up to two high impact $50,000 grants may be awarded)  Funding Priority Priority will be given to projects that meet the following criteria: Strategically address the focus area. Involve more than one agency or organization and are collaborative in nature Address a desired systemic change. Provide clear and measurable outcomes.  Geographic Areas Greater Huntsville, Alabama (Jackson, Limestone, Madison, Marshall, and/or Morgan counties). Eligible Expenses Program costs for new and/or existing programs, including reasonable staff time associated with the implementation of the program/project. Training and support for volunteers who assist in program/project implementation. Capital expenses. Eligibility Criteria All grants from this Fund must be made for charitable, religious, scientific, literary, or educational purposes to any organization that is described Code Section 170(c)(2), 501(c)(3), 2055(a)(2) or 2522(a)(2) (except for private foundations as defined by Code Section 509(a)) (“qualified organization”). Qualified organizations also include schools, religious institutions, or government agencies located in the Greater Huntsville area.  Ineligible Expenses Organizations not organized as “qualified organizations” as defined in Eligible Recipients section above Grants to individuals  Debt reduction Endowment campaigns Special events Annual campaigns Membership drives Conference expenses Political activities. For more information, visit Foundant Technologies.

Amendment 1 (June 25, 2024): The purpose of this Amendment 1 is to: 1) make administrative updates to Section 1.1, 1.2, 2.1.2, 3.1, 3.2 and 5.2.6; 2) replace Section 2.1.1 with new language pertaining to Federally Funded Research and Development Centers (FFRDCs) and Government Entities. Additionally, Section 4.2, Evaluation Criteria #2 is updated to remove the reference to Government Entities (removal is not highlighted in yellow); 3) change references from Abstract to Solution Summaries (intent behind the document is unchanged); 4) update proposal submission instructions in Section 3.2; and 5) update Section 5.1 to remove the Stage 2 Notification Letter. All changes are highlighted in yellow.Also, please note that the title of this opportunity has bee revised to eliminate confusion. The opportunity should have been titled, "Master Announcement Instruction (MAI)" instead of "ARPA-H BDF Tool Box".The Master Announcement Instructions (MAI) is a new ARPA-H announcement that aims to create standard tiered proposal submission requirements, so the amount of work required to write a proposal is commensurate with the size of the proposed effort. It also aims to reduce the up-front work required to submit cost information to reduce the barrier to entry for non-traditional performers. Module announcements that link to this MAI will provide more specific instructions about how the proposal requirements vary across tiers of effort.All responsible sources capable of satisfying the Governments needs may submit a proposal to a Module Announcement. Specifically, universities, non-profit organizations, small businesses and other than small businesses are eligible and encouraged to propose to Module Announcements.NOTE: Proposals shall NOT be submitted against the MAI. Proposals shall only be submitted against a Module Announcement.

This program provides funding and support to Massachusetts-based startups that have received Phase II SBIR or STTR awards, helping them commercialize their technologies and cover expenses like prototyping, patenting, and market research.

The Pennsylvania Department of Environmental Protection is seeking applications for its Alternative Fuels Incentive Grants. Donor Name: Pennsylvania Department of Environmental Protection State: Pennsylvania County: All Counties Type of Grant: Grant Deadline: (mm/dd/yyyy) 06/28/2024 Size of the Grant: $10,000 to $100,000 Grant Duration: Grant Duration Not Mentioned Details: AFIG has approximately $5 million in funding available to school districts, municipalities, nonprofit organizations, and businesses in Pennsylvania that want to transition to cleaner fuel transportation. Supported alternative fuels include electricity, compressed natural gas, liquefied natural gas, propane, hydrogen, hythane, biodiesel, ethanol, methanol, and other advanced biofuels. Grant funding covers: Incremental costs related to retrofitting vehicles to operate on alternative fuels; Incremental costs to purchase alternative fuel vehicles; Cost to purchase and install the necessary fleet-refueling or home-refueling equipment for alternative fuel vehicles; Cost to perform research, training, development, and demonstration of new applications or next-phase technology related to alternative fuel vehicles. Priorities Businesses whose headquarters or principal place of business are located in Pennsylvania; Zero emission vehicle projects; Medium-duty and light-duty fleet refueling infrastructure projects; Renewable natural gas vehicle and infrastructure projects; Projects located in or predominantly serving environmental justice areas; Minority-, veteran-, or woman-owned businesses. Funding Information Applicants will be eligible for a maximum grant award across all applications of $500,000. Individual application awards are still capped at $300,000. Eligibility Criteria DEP will award at least 20% of AFIG funding to the following entities, depending on applications received: Counties, townships, municipalities, or municipal authorities; Public school districts, including brick and mortar charter schools; Organizations registered as a 501(c)3 that provide services to seniors, low-income individuals and families, individuals with disabilities, veterans, or medical services of any type; Businesses that are registered with the Commonwealth as a Small Diverse Business or registered with one of the Pennsylvania Department of General Services approved third-party certifications; and Organizations that are county/local government supported or contracted to provide services to seniors, low-income individuals and families, individuals with disabilities, veterans, or medical services of any type. For more information, visit DEP.

This grant provides funding for research and development projects that advance innovative technologies in naval aviation, targeting a diverse range of applicants including universities, businesses, and non-traditional defense contractors.

Proposers must retrieve the instructions document (zip file) associated with the application package for this opportunity as there is at least one required form that must be attached to the submitted proposal package. The National Aeronautics and Space Administration (NASA) Science Mission Directorate (SMD) released its annual omnibus Research Announcement (NRA), Research Opportunities in Space and Earth Sciences (ROSES) 2024 (OMB Approval Number 2700-0092, CFDA Number 43.001) on February 14, 2024. In this case "omnibus" means that this NRA has many individual program elements, each with its own due dates and topics. All together these cover the wide range of basic and applied supporting research and technology in space and Earth sciences supported by SMD. Awards will be made as grants, cooperative agreements, contracts, and inter- or intra-agency transfers, depending on the nature of the work proposed, the proposing organization, and/or program requirements. However, most extramural research awards deriving from ROSES will be grants, and many program elements of ROSES specifically exclude contracts, because contracts would not be appropriate for the nature of the work solicited. The typical period of performance for an award is three years, but some programs may allow up to five years and others specify shorter periods. In most cases, organizations of every type, Government and private, for profit and not-for-profit, domestic and foreign (with some caveats), may submit proposals without restriction on teaming arrangements. Tables listing the program elements and due dates (Tables 2 and 3), a table that provides a very top level summary of proposal contents (Table 1), and the full text of the ROSES-2024 "Summary of Solicitation", may all be found NSPIRES at http://solicitation.nasaprs.com/ROSES2024. This synopsis is associated with one of the individual program elements within ROSES, but this is a generic summary that is posted for all ROSES elements. For specific information on this particular program element download and read the PDF of the text of this program element by going to Tables 2 or 3 of this NRA at http://solicitation.nasaprs.com/ROSES2024table2 and http://solicitation.nasaprs.com/ROSES2024table3, respectively, click the title of the program element of interest, a hypertext link will take you to a page for that particular program element. On that page, on the right side under "Announcement Documents" the link on the bottom will be to the PDF of the text of the call for proposals. For example, if one were interested in The Lunar Data Analysis Program (NNH24ZDA001N-LDAP) one would follow the link to the NSPIRES page for that program element and then to read the text of the call one would click on C.8 Lunar Data Analysis Program (.pdf) to download the text of the call. If one wanted to set it into the context of the goals, objectives and know the default rules for all elements within Appendix C, the planetary science division, one might download and read C.1 Planetary Science Research Program Overview (.pdf) from that same page. While the letters and numbers are different for each element within ROSES (A.12, B.7, etc.) the basic configuration is always the same, e.g., the letter indicates the Science Division (A is Earth Science, B is Heliophysics etc.) and whatever the letter, #1 is always the division overview. Frequently asked questions for ROSES are posted at http://science.nasa.gov/researchers/sara/faqs. Questions concerning general ROSES-2024 policies and procedures may be directed to Max Bernstein, Lead for Research, Science Mission Directorate, at [email protected], but technical questions concerning specific program elements should be directed to the point(s) of contact for that particular element, who may be found either at the end of the individual program element in the summary table of key information or on the web list of topics and points of contact at: http://science.nasa.gov/researchers/sara/program-officers-list. Not all program elements are known at the time of the release of ROSES. To be informed of new program elements or amendments to this NRA, proposers may subscribe to: (1) The SMD mailing lists (by logging in at http://nspires.nasaprs.com and checking the appropriate boxes under "Account Management" and "Email Subscriptions"), (2) The ROSES-2024 blog feed for amendments, clarifications, and corrections to at https://science.nasa.gov/researchers/solicitations/roses-2024/, and (3) The ROSES-2024 due date Google calendars (one for each science division). Instructions are at https://science.nasa.gov/researchers/sara/library-and-useful-links (link from the words due date calendar).

This grant seeks innovative proposals from a wide range of organizations, including universities and small businesses, to develop advanced technologies that enhance national defense capabilities.

Applicants are invited to apply for the Resilience Fund. Donor Name: Restaurants Care State: California County: All Counties Type of Grant: Grant Deadline: (mm/dd/yyyy) 06/30/2024 Size of the Grant: $1000 to $10,000 Grant Duration: Grant Duration Not Mentioned Details: Restaurants Care Resilience Fund is a program of the nonprofit California Restaurant Foundation. In 2024, they will be awarding grants of $5,000 to 278 independent restaurants. This fund is powered by generous gifts from PG&E, SoCalGas, and SDG&E.  Funding Information It anticipates awarding $5,000 grants to 278 small businesses Uses for Grant (select one category): Kitchen equipment: Eligible equipment must be energy efficient and qualify for rebates (Hey! That’s extra money to help pay for your equipment!). Items include steamer, rack oven, conveyor broiler, combination oven, conveyor oven, fryer, underfired broiler, convection oven, griddle, and dishwasher. You can use your $5,000 check to purchase from whichever vendor you would like. To learn more about rebates available. Technology upgrades: tell us how you’ll put this grant to work! Eligible uses include POS system, website, accounting software, HR software, inventory management, and loyalty programs.  Employee training: Been meaning to elevate your employee training and systems? Use this grant to design a training program/handbook, purchase ServSafe trainings, or join the Council of Hotel and Restaurant Trainers. Retention bonuses: Reward your best and brightest employees. You will need to state how many employees will receive grants and which positions they have (front of house, back of house, managers). The number of employees and positions do NOT impact your likelihood of getting a grant, we simply want to know how the funds will be used.  Unforeseen hardship: Within the last 12 months, has your restaurant experienced robbery/theft, vandalism, fire/flood, or natural disaster? This grant can help. Eligibility Requirements Must be an independently owned, for-profit restaurant or commercial caterer (franchises, home businesses, food trucks, and meal prep companies are not eligible) Owned by a CA resident 1-5 units Must earn no more than $3 million in annual gross revenue (combined for all units) Commercial customer of either PG&E, SoCalGas, or SDG&E Must be currently open and active for business. For more information, visit Restaurants Care.

This funding opportunity provides $10.6 million for innovative projects that improve floating offshore wind technology, targeting advancements in port infrastructure, transmission systems, and environmental monitoring tools.

The FY24 ASUDRP CA supports the establishment of a Consortium whose purpose is to identify, evaluate, and advance pharmacotherapies for alcohol, opioid, and other substance use disorders, with an emphasis on other co-occurring mental health conditions, through rigorous, collaborative research efforts that translate basic knowledge and early-stage clinical products into evidence-based treatments. The goal of this research is to maximize functioning and quality of life for Service Members, their Families, Veterans, and the American public.The proposed research must be relevant to Service Members, Veterans, military beneficiaries, and/or the American public.Each individual organization must apply to this program announcement as a Consortium Management Core (CMC) by means of a single application, and may also serve as a future research and/or trial site. The CMC will be responsible for coordinating with the Consortium Steering Committee (CSC) and Consortium Executive Committee (CEC) to prioritize, propose, conduct, and analyze basic research and clinical trials, and developing a roadmap to translate basic science knowledge into evidence-based treatments for ASUD. Clinical trials that include military and Veteran populations are encouraged.

The DoD Peer Reviewed Cancer, Virtual Cancer Center Director Award is a funding opportunity for established cancer researchers to create and lead a virtual cancer center, which aims to foster collaboration, mentorship, and innovative research among early career investigators across different cancer disciplines, with a focus on convergent science and the development of collaborative seed projects.

he U.S. Department of State, Bureau of Cyberspace and Digital Policy (CDP) announcesan open competition for organizations with the capacity and interest to carry out the project outlined in this announcement. Pending the availability of funds, CDP anticipates awarding one [1] cooperative agreement of up to $4,000,000.00 USD. CDP reserves the right to award more or less funding or make no award as is in the best interest of the US Government. This project aims to work with partner countries adopt world-leading cloud-based cybersecurity, data protection, disaster response, and recovery solutions. This project will be global in nature, with an initial focus on the Pacific Island Nations (PICs).

The City of Boulder has released the 2025 Health Equity Fund (HEF) Request for Proposals, for community-based health equity programs benefitting Boulder community members experiencing health disparities. Donor Name: City of Boulder State: County: All Counties Type of Grant: Grant Deadline: (mm/dd/yyyy) 08/12/2024 Size of the Grant: $1000 to $10,000 Grant Duration: 3 Years Details: The Health Equity Fund aims to reduce disparities and to improve health equity for people experiencing systemic socio-economic and health barriers. Examples of HEF-supported programs include health services that help prevent obesity, diabetes, heart disease and oral diseases; increased access to healthy food and clean water; wellness programs; physical fitness; and more. The City of Boulder defines health equity as the absence of systematic health disparities based on socio-economic factors, and the ability of all residents to reach their full health potential, regardless of their life circumstances. Through the HEF, the City of Boulder funds health and wellness programs that benefit City of Boulder residents experiencing health disparities, including: Residents disproportionately impacted by diseases linked to sugar-sweetened beverage (SSB) consumption or disproportionately targeted by SSB marketing; Residents who lack access to healthy food, safe water, quality health care, wellness information and health care services and systems; and Populations systemically disenfranchised due to race, ethnicity, income, age, ability, sexual orientation or gender identification. Funding Information  Proposals must request a minimum of $10,000 with at least $8,000 in eligible expenses. Grant Period The RFP is for program services performed from January 1, 2025, to December 31, 2027. Eligibility Criteria Through the HEF, the city will fund programs rather than entire organizations, institutions, or agencies. Eligible programs may be implemented in nonprofit organizations, government agencies, or public or private educational institutions (i.e., preK-12 school or college/university). Businesses and for-profit agencies should not apply. Eligible program activities may include direct services, research or collaborative approaches.  Proposal Criteria Proposals will be evaluated based on whether the proposed program:  Benefits people most affected by, or at increased risk from chronic disease linked to sugary drink consumption, or who generally experience health disparities.  Has leadership (agency board, staff and volunteers) that reflects the demographic diversity of clients served. Aligns with a selected program priority. Demonstrates sound research, evidence-based best practices. Values lived experience, cultural knowledge and wisdom.  Demonstrates strong and long-term evaluation of outcomes, or potential for such evaluation. Meaningfully engages community members experiencing health disparities in the design, implementation and/or evaluation of the proposed program. Demonstrates strong collaboration and transformative, equitable partnerships that move beyond informal relationships. Demonstrates a cost-effective approach that benefits program participants, target populations or the community. Demonstrates that the agency currently has, or demonstrates a plan for achieving sustained financial stability and organizational leadership. Exhibits diverse funding sources or a plan to achieve diverse funding.  For more information, visit COB.

Project is to increase the capacity of partner countries to develop, adopt, and implement legal frameworks that protect individual data privacy while educating key stakeholders and enabling trusted cross-border data flows and digital trade.

This project will increase the capacity of countries to develop effective regulations preventing the proliferation and misuse of commercial spyware in alignment with international best practices and advocate for commercial spyware regulatory approaches that are technically sound and rights-respecting.